After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

Viatris (NASDAQ: VTRS) could be on the verge of eating the lunch of Novo Nordisk's two golden cash cows: The diabetes drug Ozempic, and another version that's formulated for weight loss called Wegovy.

Viatris has aggressively deleveraged, now poised for growth with a robust pipeline. See why a Strong Buy rating is justified ...

Viatris Inc. closed 31.66% below its 52-week high of $13.55, which the company reached on November 25th.

The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...

Aurobindo, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir. Aurobindo, Cipla and ...

A recently launched video series from the Biotechnology Innovation Organization (BIO) seeks to show how biotech may be able ...

Viatris offers value with high free cash flow and dividends but faces growth challenges from legacy drug price erosion and ...

Viatris in Egypt, a part of global healthcare company Viatris, announced the launch of Norvasc Val, a combination therapy for ...

Valued at a market cap of $10.8 billion, Viatris Inc. (VTRS) is a healthcare company headquartered in Canonsburg, ...

Viatris's phase 3 trial for pimecrolimus 0.3% in blepharitis failed to meet its primary endpoint of debris resolution after ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, ...